PT  - JOURNAL ARTICLE
AU  - Sabe, Marwa A.
AU  - Jacob, Miriam S.
AU  - Taylor, David O.
TI  - A new class of drugs for systolic heart failure: The PARADIGM-HF study
AID  - 10.3949/ccjm.82a.14163
DP  - 2015 Oct 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 693--701
VI  - 82
IP  - 10
4099  - http://www.ccjm.org/content/82/10/693.short
4100  - http://www.ccjm.org/content/82/10/693.full
SO  - Cleve Clin J Med2015 Oct 01; 82
AB  - The PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) found a combination drug containing sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin II receptor blocker) superior to enalapril (an angiotensin-converting enzyme inhibitor) in patients with systolic heart failure. Recently approved by the US Food and Drug Administration, sacubitril-valsartan is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.